GRITSTONE BIO INC.

Gritstone bio, Inc., (gritstonebio.com) formerly Gritstone Oncology, Inc., is a biotechnology company. The Company is focused on developing targeted immunotherapies for cancer and infectious disease. The Company's programs are built on two key pillars: Gritstone EDGE artificial intelligence platform, which enables the Company to identify antigens that can be recognized by the immune system; and a potent immunotherapy platform, which is engineered to deliver the selected antigens. Its pipeline include GRANITE, SLATE, BiSAb and CORAL. GRANITE is the Company's first oncology product candidate, which is a personalized neoantigen-based immunotherapy. SLATE utilizes the same neoantigen delivery system as GRANITE but contains a fixed set of neoantigens that are shared across a subset of cancer patients. The Company has a program focused on the development of bispecific antibody (BiSAb) therapeutics using highly tumor-specific antigens. CORAL is a second-generation vaccine against SARS-CoV-2.

• GRITSTONE BIO INC.